331 related articles for article (PubMed ID: 33842885)
1. Detection of β-amyloid positivity in Alzheimer's Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers.
Tosun D; Veitch D; Aisen P; Jack CR; Jagust WJ; Petersen RC; Saykin AJ; Bollinger J; Ovod V; Mawuenyega KG; Bateman RJ; Shaw LM; Trojanowski JQ; Blennow K; Zetterberg H; Weiner MW
Brain Commun; 2021; 3(2):fcab008. PubMed ID: 33842885
[No Abstract] [Full Text] [Related]
2. Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease.
Benedet AL; Leuzy A; Pascoal TA; Ashton NJ; Mathotaarachchi S; Savard M; Therriault J; Kang MS; Chamoun M; Schöll M; Zimmer ER; Gauthier S; Labbe A; Zetterberg H; Rosa-Neto P; Blennow K;
Brain; 2020 Dec; 143(12):3793-3804. PubMed ID: 33210117
[TBL] [Abstract][Full Text] [Related]
3. β-Amyloid discordance of cerebrospinal fluid and positron emission tomography imaging shows distinct spatial tau patterns.
Jiang C; Wang Q; Xie S; Chen Z; Fu L; Peng Q; Liang Y; Guo H; Guo T;
Brain Commun; 2022; 4(2):fcac084. PubMed ID: 35441134
[TBL] [Abstract][Full Text] [Related]
4. Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease.
Pereira JB; Janelidze S; Smith R; Mattsson-Carlgren N; Palmqvist S; Teunissen CE; Zetterberg H; Stomrud E; Ashton NJ; Blennow K; Hansson O
Brain; 2021 Dec; 144(11):3505-3516. PubMed ID: 34259835
[TBL] [Abstract][Full Text] [Related]
5. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages.
Pascoal TA; Benedet AL; Tudorascu DL; Therriault J; Mathotaarachchi S; Savard M; Lussier FZ; Tissot C; Chamoun M; Kang MS; Stevenson J; Massarweh G; Guiot MC; Soucy JP; Gauthier S; Rosa-Neto P
Brain; 2021 Dec; 144(11):3517-3528. PubMed ID: 34515754
[TBL] [Abstract][Full Text] [Related]
7. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.
Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW;
Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191
[TBL] [Abstract][Full Text] [Related]
8. Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum.
Moscoso A; Grothe MJ; Ashton NJ; Karikari TK; Rodriguez JL; Snellman A; Suárez-Calvet M; Zetterberg H; Blennow K; Schöll M;
Brain; 2021 Feb; 144(1):325-339. PubMed ID: 33257949
[TBL] [Abstract][Full Text] [Related]
9. Blood Derived Amyloid Biomarkers for Alzheimer's Disease Prevention.
Udeh-Momoh C; Zheng B; Sandebring-Matton A; Novak G; Kivipelto M; Jönsson L; Middleton L
J Prev Alzheimers Dis; 2022; 9(1):12-21. PubMed ID: 35098969
[TBL] [Abstract][Full Text] [Related]
10. Plasma levels of phosphorylated tau 181 are associated with cerebral metabolic dysfunction in cognitively impaired and amyloid-positive individuals.
Lussier FZ; Benedet AL; Therriault J; Pascoal TA; Tissot C; Chamoun M; Mathotaarachchi S; Savard M; Ashton NJ; Karikari TK; Rodriguez JL; Snellman A; Bezgin G; Kang MS; Fernandez Arias J; Wang YT; Gauthier S; Zetterberg H; Blennow K; Rosa-Neto P;
Brain Commun; 2021; 3(2):fcab073. PubMed ID: 33959711
[TBL] [Abstract][Full Text] [Related]
11. Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study.
Jack CR; Wiste HJ; Weigand SD; Therneau TM; Knopman DS; Lowe V; Vemuri P; Mielke MM; Roberts RO; Machulda MM; Senjem ML; Gunter JL; Rocca WA; Petersen RC
Lancet Neurol; 2017 Jun; 16(6):435-444. PubMed ID: 28456479
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease.
Moscoso A; Grothe MJ; Ashton NJ; Karikari TK; Lantero Rodríguez J; Snellman A; Suárez-Calvet M; Blennow K; Zetterberg H; Schöll M;
JAMA Neurol; 2021 Apr; 78(4):396-406. PubMed ID: 33427873
[TBL] [Abstract][Full Text] [Related]
13. Leveraging speech and artificial intelligence to screen for early Alzheimer's disease and amyloid beta positivity.
Fristed E; Skirrow C; Meszaros M; Lenain R; Meepegama U; Papp KV; Ropacki M; Weston J
Brain Commun; 2022; 4(5):fcac231. PubMed ID: 36381988
[TBL] [Abstract][Full Text] [Related]
14. APOE ε4 gene dose effect on imaging and blood biomarkers of neuroinflammation and beta-amyloid in cognitively unimpaired elderly.
Snellman A; Ekblad LL; Tuisku J; Koivumäki M; Ashton NJ; Lantero-Rodriguez J; Karikari TK; Helin S; Bucci M; Löyttyniemi E; Parkkola R; Karrasch M; Schöll M; Zetterberg H; Blennow K; Rinne JO
Alzheimers Res Ther; 2023 Apr; 15(1):71. PubMed ID: 37016464
[TBL] [Abstract][Full Text] [Related]
15. Predicting amyloid PET and tau PET stages with plasma biomarkers.
Jack CR; Wiste HJ; Algeciras-Schimnich A; Figdore DJ; Schwarz CG; Lowe VJ; Ramanan VK; Vemuri P; Mielke MM; Knopman DS; Graff-Radford J; Boeve BF; Kantarci K; Cogswell PM; Senjem ML; Gunter JL; Therneau TM; Petersen RC
Brain; 2023 May; 146(5):2029-2044. PubMed ID: 36789483
[TBL] [Abstract][Full Text] [Related]
16. Is tau in the absence of amyloid on the Alzheimer's continuum?: A study of discordant PET positivity.
Weigand AJ; Bangen KJ; Thomas KR; Delano-Wood L; Gilbert PE; Brickman AM; Bondi MW;
Brain Commun; 2020; 2(1):fcz046. PubMed ID: 32051933
[TBL] [Abstract][Full Text] [Related]
17. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.
Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN;
Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591
[TBL] [Abstract][Full Text] [Related]
18. The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects.
Smith R; Strandberg O; Mattsson-Carlgren N; Leuzy A; Palmqvist S; Pontecorvo MJ; Devous MD; Ossenkoppele R; Hansson O
Brain; 2020 Dec; 143(12):3805-3815. PubMed ID: 33439987
[TBL] [Abstract][Full Text] [Related]
19. Predicting amyloid PET positivity using plasma p-tau181 and other blood-based biomarkers.
Kwon HS; Lee EH; Kim HJ; Park SH; Park HH; Jeong JH; Koh SH; Choi SH; Lee JH
Alzheimers Dement (Amst); 2023; 15(4):e12502. PubMed ID: 38026758
[TBL] [Abstract][Full Text] [Related]
20. Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.
Fortea J; Vilaplana E; Carmona-Iragui M; Benejam B; Videla L; Barroeta I; Fernández S; Altuna M; Pegueroles J; Montal V; Valldeneu S; Giménez S; González-Ortiz S; Muñoz L; Estellés T; Illán-Gala I; Belbin O; Camacho V; Wilson LR; Annus T; Osorio RS; Videla S; Lehmann S; Holland AJ; Alcolea D; Clarimón J; Zaman SH; Blesa R; Lleó A
Lancet; 2020 Jun; 395(10242):1988-1997. PubMed ID: 32593336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
